Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...

Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...

Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan) for treating adults with paroxysmal nocturnal haemoglobinuria (PNH).

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Management holds 11th Annual ESG Investor Virtual Event on December 9 at 10 am. NVS ).webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422′ target= ‘_blank’; rel=’nofollow’>Webcast Link Discover ...

Novartis suffered a legal setback on Wednesday as the company failed to persuade a U.S. appeals court to halt MSN ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset ...